Gastroenterology
Intussusception
4
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Intussusception is an early-stage landscape with 4 programs across 4 companies. The most active players are Pfizer, GSK, Merck & Co.. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 2
No programs
Phase 3
No programs
Approved2
Analysis
Modality Breakdown
4programs
Small molecule250%
Vaccine250%
Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
3
clinical trials
Completed2 · 67%
Recruiting1 · 33%
Clinical Trials
Trial Activity
Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception
Recruiting·—·N/A·NCT02691858·80 enrolled
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
Completed·—·Phase 4·NCT02542462·144 enrolled
Follow-up and Steroid Treatment Results in Intussusception
Completed·—·Phase 1/2·NCT05640375·92 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)